ABBV has WON their case against CHRS with regard to Humira patent infringment

[anonymous]

ABBV has WON their case against CHRS with regard to Humira patent infringment YUGE ABBV GAIN ...CHRS DOWN 13%

 

[anonymous]

Ricky Gonzalez WINS AGAIN
Coherus BioSciences, Inc. (Nasdaq: CHRS) announced that it has received a decision from the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office denying institution of Coherus petition for Inter Partes Review (IPR) of ABBV U.S. Patent 9,114,166 (166 Patent) related to AbbVie’s HUMIRA (adalimumab) formulation.

 

[anonymous]

CEO DENNY LANFEAR CHOKED BIG TIME
“While we are disappointed by this outcome it is important to note that our longstanding strategy has been to develop and preserve multiple options pursuant to adalimumab formulation intellectual property. There are additional scientific and legal approaches available to address the various formulation intellectual property challenges, and all of the arguments raised in our IPR petition remain available in a District Court proceeding,”